By Tiffany Yesavag – Genetic Bioengineering & Biotechnology News –
Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant excitement in both the medical and investment communities in recent years, its success has predominantly been confined to treating B-cell leukemias and lymphomas. To assess the current state of CAR T-cell therapy—including advancements in manufacturing processes and the potential for treating solid tumors—GEN spoke with four leading companies in the field.
